Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SpingWorks

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

Alector kicks off next wave of biotech IPOs

US biotech raising money again

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

UK biotech booms in 2018, despite Brexit worries

Industry attracted a record-breaking £2.2bn in investment last year

- PMLiVE

Pfizer takeover rumour ignites Amarin shares

Fish oil product shows great promise

- PMLiVE

Moderna CEO makes case for firm’s lofty valuation

mRNA specialist has to convince investors after stocks slide

- PMLiVE

After December slump, what’s in store for biotech in 2019?

Analysts say 2019 could be a "big year for proceeds if not for deal count"

- PMLiVE

GSK and Pfizer to create combined consumer health titan

Spin-out will allow GSK to focus on prescription drugs and vaccines

Navigating the antibiotic resistance crisis

Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Blue Latitude Health

Report: Achieving launch excellence in the challenging healthcare markets of today

Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links